Congestive Heart Failure (Heart Failure) - Pipeline Review, H1 2019

Global Markets Direct’s, ‘Congestive Heart Failure (Heart Failure) - Pipeline Review, H1 2019’, provides an overview of the Congestive Heart Failure (Heart Failure) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Congestive Heart Failure (Heart Failure), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Congestive Heart Failure (Heart Failure) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Congestive Heart Failure (Heart Failure)

- The report reviews pipeline therapeutics for Congestive Heart Failure (Heart Failure) by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Congestive Heart Failure (Heart Failure) therapeutics and enlists all their major and minor projects

- The report assesses Congestive Heart Failure (Heart Failure) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Congestive Heart Failure (Heart Failure)

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Congestive Heart Failure (Heart Failure)

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Congestive Heart Failure (Heart Failure) pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Actelion Pharmaceuticals Ltd

Adrenomed AG

Amgen Inc

Araim Pharmaceuticals Inc

ARCA biopharma Inc

Arena Pharmaceuticals Inc

Ascendia Pharmaceuticals LLC

Astellas Pharma Inc

AstraZeneca Plc

Athersys ...

Actelion Pharmaceuticals Ltd

Adrenomed AG

Amgen Inc

Araim Pharmaceuticals Inc

ARCA biopharma Inc

Arena Pharmaceuticals Inc

Ascendia Pharmaceuticals LLC

Astellas Pharma Inc

AstraZeneca Plc

Athersys Inc

Bayer AG

BEAT BioTherapeutics Corp

Betagenon AB

BioCardia Inc

BlueRock Therapeutics

Boehringer Ingelheim GmbH

Bristol-Myers Squibb Co

C&C BioPharma LLC

Capricor Therapeutics Inc

Cardiol Therapeutics Inc

CCRP Therapeutics GmbH

Celixir Ltd

Daiichi Sankyo Co Ltd

F. Hoffmann-La Roche Ltd

Hemostemix Inc

Immunwork Inc

Innopharmax Inc

Inserm Transfert SA

Intra-Cellular Therapies Inc

Japan Tobacco Inc

Juventas Therapeutics Inc

KBP BioSciences Co Ltd

La Jolla Pharmaceutical Company

Lead Discovery Center GmbH

Les Laboratoires Servier SAS

Lexicon Pharmaceuticals Inc

Merck & Co Inc

Mesoblast Ltd

Miragen Therapeutics Inc

Mitsubishi Tanabe Pharma Corp

Moderna Therapeutics Inc

MyoKardia Inc

NanoCor Therapeutics Inc

Novartis AG

Otsuka Holdings Co Ltd

Oxstem Ltd

Palatin Technologies Inc

Paradigm Biopharmaceuticals Ltd

Pfizer Inc

PharmaIN Corp

PhaseBio Pharmaceuticals Inc

Q BioMed Inc

Quantum Genomics SA

Recardio GmbH

Renova Therapeutics Inc

resTORbio Inc

Ribomic Inc

Saje Pharma LLC

Sarfez Pharmaceuticals Inc

Senju Pharmaceutical Co Ltd

Shenzhen Salubris Pharmaceuticals Co Ltd

Shin Poong PharmCo Ltd

Sorrento Therapeutics Inc

Stemedica Cell Technologies Inc

Sun Pharma Advanced Research Company Ltd

Takeda Pharmaceutical Co Ltd

Theravance Biopharma Inc

Toa Eiyo Ltd

Torrent Pharmaceuticals Ltd

U.S. Stem Cell Inc

Vifor Pharma Ltd

Windtree Therapeutics Inc

XyloCor Therapeutics Inc

Zensun (Shanghai) Sci & Tech Co Ltd

Table of Contents

Table of Contents

Table of Contents

Introduction

Congestive Heart Failure (Heart Failure) – Overview

Congestive Heart Failure (Heart Failure) – Therapeutics Development

Congestive Heart Failure (Heart Failure ...

Table of Contents

Table of Contents

Introduction

Congestive Heart Failure (Heart Failure) – Overview

Congestive Heart Failure (Heart Failure) – Therapeutics Development

Congestive Heart Failure (Heart Failure) – Therapeutics Assessment

Congestive Heart Failure (Heart Failure) – Companies Involved in Therapeutics Development

Congestive Heart Failure (Heart Failure) – Drug Profiles

Congestive Heart Failure (Heart Failure) – Dormant Projects

Congestive Heart Failure (Heart Failure) – Discontinued Products

Congestive Heart Failure (Heart Failure) – Product Development Milestones

Appendix

List of Tables

List of Tables

Number of Products under Development for Congestive Heart Failure (Heart Failure), H1 2019

Number of Products under Development by Companies, H1 2019 ...

List of Tables

Number of Products under Development for Congestive Heart Failure (Heart Failure), H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products under Development by Universities/Institutes, H1 2019

Number of Products under Development by Universities/Institutes, H1 2019 (Contd..1), H1 2019

Products under Development by Companies, H1 2019

Products under Development by Universities/Institutes, H1 2019

Products under Development by Universities/Institutes, H1 2019 (Contd..1), H1 2019

Number of Products by Stage and Target, H1 2019

Number of Products by Stage and Mechanism of Action, H1 2019

Number of Products by Stage and Route of Administration, H1 2019

Number of Products by Stage and Molecule Type, H1 2019

Congestive Heart Failure (Heart Failure) – Pipeline by Actelion Pharmaceuticals Ltd, H1 2019

Congestive Heart Failure (Heart Failure) – Pipeline by Adrenomed AG, H1 2019

Congestive Heart Failure (Heart Failure) – Pipeline by Amgen Inc, H1 2019

Congestive Heart Failure (Heart Failure) – Pipeline by Araim Pharmaceuticals Inc, H1 2019

Congestive Heart Failure (Heart Failure) – Pipeline by ARCA biopharma Inc, H1 2019

Congestive Heart Failure (Heart Failure) – Pipeline by Arena Pharmaceuticals Inc, H1 2019

Congestive Heart Failure (Heart Failure) – Pipeline by Ascendia Pharmaceuticals LLC, H1 2019

Congestive Heart Failure (Heart Failure) – Pipeline by Astellas Pharma Inc, H1 2019

Congestive Heart Failure (Heart Failure) – Pipeline by AstraZeneca Plc, H1 2019

Congestive Heart Failure (Heart Failure) – Pipeline by Athersys Inc, H1 2019

Congestive Heart Failure (Heart Failure) – Pipeline by Bayer AG, H1 2019

Congestive Heart Failure (Heart Failure) – Pipeline by BEAT BioTherapeutics Corp, H1 2019

Congestive Heart Failure (Heart Failure) – Pipeline by Betagenon AB, H1 2019

Congestive Heart Failure (Heart Failure) – Pipeline by BioCardia Inc, H1 2019

Congestive Heart Failure (Heart Failure) – Pipeline by BlueRock Therapeutics, H1 2019

Congestive Heart Failure (Heart Failure) – Pipeline by Boehringer Ingelheim GmbH, H1 2019

Congestive Heart Failure (Heart Failure) – Pipeline by Bristol-Myers Squibb Co, H1 2019

Congestive Heart Failure (Heart Failure) – Pipeline by C&C BioPharma LLC, H1 2019

Congestive Heart Failure (Heart Failure) – Pipeline by Capricor Therapeutics Inc, H1 2019

Congestive Heart Failure (Heart Failure) – Pipeline by Cardiol Therapeutics Inc, H1 2019

Congestive Heart Failure (Heart Failure) – Pipeline by CCRP Therapeutics GmbH, H1 2019

Congestive Heart Failure (Heart Failure) – Pipeline by Celixir Ltd, H1 2019

Congestive Heart Failure (Heart Failure) – Pipeline by Daiichi Sankyo Co Ltd, H1 2019

Congestive Heart Failure (Heart Failure) – Pipeline by F. Hoffmann-La Roche Ltd, H1 2019

Congestive Heart Failure (Heart Failure) – Pipeline by Hemostemix Inc, H1 2019

Congestive Heart Failure (Heart Failure) – Pipeline by Immunwork Inc, H1 2019

Congestive Heart Failure (Heart Failure) – Pipeline by Innopharmax Inc, H1 2019

List of Figures

List of Figures

Number of Products under Development for Congestive Heart Failure (Heart Failure), H1 2019

Number of Products under Development by Companies, H1 2019 ...

List of Figures

Number of Products under Development for Congestive Heart Failure (Heart Failure), H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products under Development by Universities/Institutes, H1 2019

Number of Products by Top 10 Targets, H1 2019

Number of Products by Stage and Top 10 Targets, H1 2019

Number of Products by Top 10 Mechanism of Actions, H1 2019

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2019

Number of Products by Top 10 Routes of Administration, H1 2019

Number of Products by Stage and Top 10 Routes of Administration, H1 2019

Number of Products by Top 10 Molecule Types, H1 2019

Number of Products by Stage and Top 10 Molecule Types, H1 2019

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports